Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841
Brief Summary: The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).


Options:
A: Arm Label: Bimekizumab Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Adalimumab Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bimekizumab, Drug: Adalimumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2 | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2
B: Arm Label: PF-06700841 Oral Solution/Suspension; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 oral solution/suspension | Arm Label: PF-06700841 Tablet; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: PF-06700841 oral solution/suspension; Assigned to Arm(s): PF-06700841 Oral Solution/Suspension | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PF-06700841 tablet; Assigned to Arm(s): PF-06700841 Tablet
C: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab | Arm Label: Risankizumab 75 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for risankizumab | Arm Label: Risankizumab 150 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab 150 mg (Part A), Risankizumab 75 mg (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Risankizumab 75 mg (Part A)
D: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate

Answer: B